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Clinical PerspectiveWhat Is New?Crossover from experimental to control group is associated with outcomes of cardiac surgery randomized controlled trials.What Are the Clinical Implications?Crossover should be minimized at designing stage and carefully appraised after study completion.

Introduction {#jah34568-sec-0008}
============

Randomized controlled trials (RCTs) are considered the gold standard to compare different treatments.[1](#jah34568-bib-0001){ref-type="ref"}, [2](#jah34568-bib-0002){ref-type="ref"} If duly adhered to, the process of randomization enables the homogeneous distribution of known and unknown risk factors and confounders between treatment arms, thereby allowing for minimization of the bias around the point estimate for a given treatment effect.[2](#jah34568-bib-0002){ref-type="ref"} However, within RCTs, the crossover of subjects from one group to the other dilutes the treatment effect and, even if occurring randomly, reduces the statistical power of the intention‐to‐treat analysis.[3](#jah34568-bib-0003){ref-type="ref"}, [4](#jah34568-bib-0004){ref-type="ref"} With high rates of crossover, and even more so when crossover is not random but caused by specific reasons related to the intervention, such as lower confidence or expertise with the experimental therapy, the internal validity of RCTs may be jeopardized and biased effect estimates may ensue, misinforming researchers, clinicians, and patients.[5](#jah34568-bib-0005){ref-type="ref"}, [6](#jah34568-bib-0006){ref-type="ref"} Crossover is particularly worrisome when occurring prevalently from one group to the other (1‐way crossover). When the prevalent direction is from the experimental to the control arm, crossover may drive the effect estimates toward the null hypothesis, even when the experimental treatment is superior to the control intervention.[7](#jah34568-bib-0007){ref-type="ref"} On the other hand, crossover from control to experimental group may lead to underestimation of the adverse effects associated with a potentially more hazardous experimental treatment.

Surgical RCTs are particularly at risk of crossover issues because of the complex, intricate, and operator‐dependent nature of the intervention, the likelihood of a learning curve, the need for specific technical expertise, and the lapse between randomization and intervention.[8](#jah34568-bib-0008){ref-type="ref"}, [9](#jah34568-bib-0009){ref-type="ref"}, [10](#jah34568-bib-0010){ref-type="ref"} For instance, randomization to a novel technique in cardiovascular surgery is typically completed before the operation, whereas the actual feasibility of the procedure can only be fully appraised intraoperatively. Moreover, in surgical RCTs, crossover not only dilutes the potential treatment effect, but may also be a surrogate for lack of confidence or expertise with the novel treatment.[10](#jah34568-bib-0010){ref-type="ref"} This can potentially influence the study results, even beyond the purely statistical effect of crossover.

Given the lack of dedicated investigations on the prevalence and impact of crossover in cardiac surgery, where treatment applicability considerations are arguably among the highest in medicine, the importance and frequency of these interventions for millions of patients worldwide, and the informative, prototypical role of cardiac surgery treatments on medical practice at large, we aimed to systematically evaluate the relationship between crossover rate and outcomes in all RCTs that compared cardiac surgical interventions, by using a meta‐epidemiologic approach.[11](#jah34568-bib-0011){ref-type="ref"} Specifically, our main hypothesis was that crossover may unfavorably impact effect estimates, with a high crossover rate diluting clinical effects and, thus, undermining study validity and conclusions.

Methods {#jah34568-sec-0009}
=======

The data that support the findings of this study are available from the corresponding author on reasonable request.

Design {#jah34568-sec-0010}
------

This meta‐epidemiologic study was conducted in keeping with current reviewing practice recommendations,[11](#jah34568-bib-0011){ref-type="ref"} and it is reported according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses checklist (Figure [S1](#jah34568-sup-0001){ref-type="supplementary-material"}).[12](#jah34568-bib-0012){ref-type="ref"} The analysis was preregistered on the PROSPERO international database of prospectively registered systematic reviews (identifier: CRD42019123022). There was no individual patient involvement in this study; as such, research ethics board approval was not required.

Search Strategy {#jah34568-sec-0011}
---------------

A comprehensive search to identify RCTs that compared ≥2 adult cardiac surgical interventions was performed in the following databases: Ovid MEDLINE (all; 1990 to February 2019); Ovid EMBASE (1990 to February 2019); and The Cochrane Library (Wiley). The search strategy included the following terms: "CABG," "off‐pump coronary surgery," "on‐pump coronary surgery," "arterial grafts," "bilateral internal mammary artery," "bilateral internal thoracic artery," "radial artery," "right gastroepiploic artery," "arterial revascularization," "saphenous vein graft," "mitral valve repair," "mitral valve replacement," "tricuspid valve," "aortic valve replacement," "aortic valve repair," "heart transplant," and "ventricular assist device" (full search strategy available in Table [S1](#jah34568-sup-0001){ref-type="supplementary-material"}). Studies performed on patients with congenital cardiac abnormalities were not included in the search.

Study Selection {#jah34568-sec-0012}
---------------

Searches across the chosen databases retrieved a total of 10 619 results. After deduplication and removal of nonpertinent articles, 2 independent reviewers (A.D.F., M.D.M.) screened a total of 152 articles. Titles and abstracts were reviewed against predefined inclusion/exclusion criteria. A third independent reviewer (G.F.) confirmed adequacy of studies on the basis of predefined inclusion criteria. Articles were considered for inclusion if they were RCTs with a planned sample size ≥100 patients, published between 1990 and February 2019, comparing ≥2 cardiac surgical interventions in adult patients, and written in English. Studies that compared different devices (not different surgical techniques), surgical versus nonsurgical interventions, and pharmacological or percutaneous treatments were not included. Studies using a noninferiority or equivalence design and for which the primary outcomes or crossover rate was not specified were also excluded. In case of several publications with overlapping study populations, the report that detailed the largest sample size with the longest follow‐up available was selected. In case of multiple publications from the same RCT providing different outcomes, all publications were included. Multiple outcomes from the same trial were included when the sample size was powered for all of them.

The full text of preliminary screened studies was retrieved for a second round of eligibility screening. Disagreements were resolved by the first author (M.G.). Reference lists of the included articles were also searched, and additional studies were included (ie, backward snowballing). The Preferred Reporting Items for Systematic Reviews and Meta‐Analyses flow diagram is shown as Figure [S1](#jah34568-sup-0001){ref-type="supplementary-material"}.

Data Extraction {#jah34568-sec-0013}
---------------

Two investigators (A.D.F., M.D.M.) performed data extraction independently, and data were later verified by a third investigator (M.G.) for accuracy. The following variables were included: number of studies, number of study reports, total number of comparisons, number of studies with co--primary end points, year of publication, number of multicenter studies, number of centers in multicenter studies, number of off‐pump coronary artery bypass graft (CABG) trials, statistical power (%), expected relative risk (RR) reduction (%), sample size, follow‐up (months), internal validity, according to Cochrane Risk of Bias Tool, crossover from experimental to control group (%), crossover from control to experimental group (%), total crossover (%), relative crossover (%), main findings, RR for primary end point, and RR for mortality. We also generated a *relative crossover estimate* (defined as crossover from experimental to control group divided by crossover from control to experimental group) and a *total crossover estimate* (defined as the sum of crossover from experimental to control group plus crossover from control to experimental group).

Assessment of the Quality of Individual Studies and the Overall Quality of Evidence {#jah34568-sec-0014}
-----------------------------------------------------------------------------------

The quality of the included studies was assessed by using the Cochrane Risk of Bias Tool for assessing the internal validity of RCTs.[13](#jah34568-bib-0013){ref-type="ref"}

Outcomes {#jah34568-sec-0015}
--------

The primary outcome was the effect estimate for the primary end point of each included RCT, and the secondary outcome was all‐cause mortality, both appraised as RR at the longest follow‐up available. Whenever possible, RR was recalculated for each study and comparison. When only hazard ratios were reported and RR calculation was unfeasible, hazard ratios were considered as adequate estimators of RR.

Statistical Analysis {#jah34568-sec-0016}
--------------------

Regardless of the way the individual trial was initially reported, for this review, all RRs were calculated as \>1 favored the control group and \<1 favored the experimental arm.

Continuous variables are reported as median (first quartile; third quartile), and categorical variables are reported as count (%). Exploratory inferential analysis was based on χ^2^ or Wilcoxon rank‐sum tests. The main inferential analysis was based on random effects pairwise meta‐analysis and on meta‐regression, using the logarithm of RR (LogRR) as dependent variable, with graphical synthesis by means of forest and L\'Abbè plots. Inconsistency was appraised as I^2^, τ^2^, and χ^2^ tests, with between‐subgroup heterogeneity tested with an inverse‐variance‐weighting model. Adjusted *R* ^2^ was also used to describe predictive ability. A sensitivity analysis using absolute LogRR (ie, \|LogRR\|) was also conducted, as it may capture extreme effects better when treatments undergoing comparison may have been defined experimental versus standard inappropriately. In addition, we also conducted an exploratory analysis to identify features independently associated with high crossover rate. Publication bias and small study effects were explored by visual inspection of funnel plots and computing Egger and Begg tests. Effects are reported as point estimates (95% CIs). Computations were performed with Stata 13 (StataCorp, College Station, TX). Studies having a continuous variable as the primary outcome measure were not included in the main analysis.

Results {#jah34568-sec-0017}
=======

After searches and selection, 60 reports (accounting for 67 comparisons) from 47 RCTs were identified (25 440 total patients) (Table [1](#jah34568-tbl-0001){ref-type="table"}; references of the included RCTs are provided in the supplemental material). Most RCTs focused on off‐pump versus on‐pump CABG; 5 focused on radial versus saphenous vein grafting; 2 focused on repair versus replacement of the mitral valve; 2 focused on total arterial revascularization versus left internal thoracic artery plus saphenous vein grafting; and the remaining RCTs focused on CABG, mitral valve disease, and aortic valve disease (Table [S2](#jah34568-sup-0001){ref-type="supplementary-material"}). Most studies (n=27 \[57.4%\]) were limited to 1 or 2 centers. The a priori median expected RR reduction was 29%, the median sample size was 251 subjects, and the median follow‐up was 12 months. The internal validity of included studies was variable, with few studies at low risk of bias in all appraised dimensions, and several at high risk (Table [S3](#jah34568-sup-0001){ref-type="supplementary-material"}). Crossover from the experimental to control group occurred in 7.0% (first quartile, 2.0%; third quartile, 9.7%) of patients, whereas crossover from the control to experimental group took place in 1.3% (first quartile, 0%; third quartile, 3.6%) of patients. Inferential estimates of the primary end point favored the experimental treatment in 13 RCTs and the control group in 4, and were not significantly different in 50 cases. The median RR for primary end point was 0.95 (95% CI, 0.65--1.12), and the median RR for mortality was 0.99 (95% CI, 0.80--1.28).

###### 

Main Features of Included Studies

  Feature                                                     Value, Count (%) or Median (First Quartile; Third Quartile)
  ----------------------------------------------------------- -------------------------------------------------------------
  Studies                                                     47
  Study reports                                               60
  Total no. of comparisons                                    67
  Studies with co--primary end points                         8 (17.8)
  Year of publication                                         2009 (2004; 2012)
  Multicenter studies                                         20 (42.6)
  No. of centers in multicenter studies                       15 (7; 24)
  Treatment features                                          
  Coronary artery bypass graft trials                         42 (89.4)
  Off‐pump coronary artery bypass graft trials                27 (57.4)
  Valve trials                                                9 (19.2)
  Experimental group more invasive than control group         14 (29.8)
  End point features                                          
  Mortality end point                                         24 (51.1)
  Clinical end point                                          22 (46.8)
  Patency end point                                           13 (27.7)
  Statistical power, %                                        80 (80; 90)
  Expected relative risk reduction, %                         29 (18; 37)
  Sample size                                                 251 (128; 401)
  Follow‐up, mo                                               12 (1; 36)
  Internal validity according to Cochrane Risk of Bias Tool   
  High                                                        8 (11.9)
  Moderate or uncertain                                       48 (71.6)
  Low                                                         11 (16.4)
  Crossover from experimental to control group, %             7.0 (2.0; 9.7)
  Crossover from control to experimental group, %             1.3 (0; 3.6)
  Total crossover, %                                          7.8 (3.0; 10.7)
  Relative crossover, %                                       3.6 (1.0; 19.0)
  Main findings                                               
  Favors experimental group                                   13 (19.4)
  Favors control group                                        4 (6.0)
  Nonsignificant                                              50 (74.6)
  Relative risk for primary end point                         0.95 (0.65; 1.12)
  Relative risk for mortality                                 0.99 (0.80; 1.28)

A meta‐epidemiologic analysis that explores the study features associated with higher versus lower than median crossover rate, from experimental to control group, is provided in Table [2](#jah34568-tbl-0002){ref-type="table"}. Off‐pump CABG trials showed a higher prevalence of crossover from experimental to control group, as did studies on valve surgery, allocating less invasive treatments to the experimental arm and focusing on a mortality or clinical end point, low, moderate, or uncertain internal validity, according to the Cochrane Risk of Bias Tool assessment, and nonsignificant inferential estimates for the trial\'s primary end point (all *P*\<0.05 at χ^2^ test). Crossover from control to experimental group was significantly associated with multicenter setting, focus on a clinical end point, and large sample size (all *P*\<0.05 at χ^2^ test). Accordingly, the RR for primary end point was higher in RCTs with high crossover rate from experimental to control group (*P*=0.040 by meta‐regression analysis) (Table [3](#jah34568-tbl-0003){ref-type="table"}) (Figure [1](#jah34568-fig-0001){ref-type="fig"}),[14](#jah34568-bib-0014){ref-type="ref"}, [15](#jah34568-bib-0015){ref-type="ref"}, [16](#jah34568-bib-0016){ref-type="ref"}, [17](#jah34568-bib-0017){ref-type="ref"}, [18](#jah34568-bib-0018){ref-type="ref"}, [19](#jah34568-bib-0019){ref-type="ref"}, [20](#jah34568-bib-0020){ref-type="ref"}, [21](#jah34568-bib-0021){ref-type="ref"}, [22](#jah34568-bib-0022){ref-type="ref"}, [23](#jah34568-bib-0023){ref-type="ref"}, [24](#jah34568-bib-0024){ref-type="ref"}, [25](#jah34568-bib-0025){ref-type="ref"}, [26](#jah34568-bib-0026){ref-type="ref"}, [27](#jah34568-bib-0027){ref-type="ref"}, [28](#jah34568-bib-0028){ref-type="ref"}, [29](#jah34568-bib-0029){ref-type="ref"}, [30](#jah34568-bib-0030){ref-type="ref"}, [31](#jah34568-bib-0031){ref-type="ref"}, [32](#jah34568-bib-0032){ref-type="ref"}, [33](#jah34568-bib-0033){ref-type="ref"}, [34](#jah34568-bib-0034){ref-type="ref"}, [35](#jah34568-bib-0035){ref-type="ref"}, [36](#jah34568-bib-0036){ref-type="ref"}, [37](#jah34568-bib-0037){ref-type="ref"}, [38](#jah34568-bib-0038){ref-type="ref"}, [39](#jah34568-bib-0039){ref-type="ref"}, [40](#jah34568-bib-0040){ref-type="ref"}, [41](#jah34568-bib-0041){ref-type="ref"}, [42](#jah34568-bib-0042){ref-type="ref"}, [43](#jah34568-bib-0043){ref-type="ref"}, [44](#jah34568-bib-0044){ref-type="ref"}, [45](#jah34568-bib-0045){ref-type="ref"}, [46](#jah34568-bib-0046){ref-type="ref"}, [47](#jah34568-bib-0047){ref-type="ref"}, [48](#jah34568-bib-0048){ref-type="ref"}, [49](#jah34568-bib-0049){ref-type="ref"} with similar findings pertaining to the RR for mortality (*P*=0.015 by meta‐regression analysis) (Figure [S2](#jah34568-sup-0001){ref-type="supplementary-material"}). However, no significant associations were found between crossover from control to experimental group and study findings (*P*=0.065 at χ^2^ test), nor RR for primary end point (*P*=0.726 at meta‐regression analysis) (Figure [2](#jah34568-fig-0002){ref-type="fig"})[14](#jah34568-bib-0014){ref-type="ref"}, [15](#jah34568-bib-0015){ref-type="ref"}, [16](#jah34568-bib-0016){ref-type="ref"}, [17](#jah34568-bib-0017){ref-type="ref"}, [18](#jah34568-bib-0018){ref-type="ref"}, [19](#jah34568-bib-0019){ref-type="ref"}, [20](#jah34568-bib-0020){ref-type="ref"}, [21](#jah34568-bib-0021){ref-type="ref"}, [22](#jah34568-bib-0022){ref-type="ref"}, [23](#jah34568-bib-0023){ref-type="ref"}, [24](#jah34568-bib-0024){ref-type="ref"}, [25](#jah34568-bib-0025){ref-type="ref"}, [26](#jah34568-bib-0026){ref-type="ref"}, [27](#jah34568-bib-0027){ref-type="ref"}, [28](#jah34568-bib-0028){ref-type="ref"}, [29](#jah34568-bib-0029){ref-type="ref"}, [30](#jah34568-bib-0030){ref-type="ref"}, [31](#jah34568-bib-0031){ref-type="ref"}, [32](#jah34568-bib-0032){ref-type="ref"}, [33](#jah34568-bib-0033){ref-type="ref"}, [34](#jah34568-bib-0034){ref-type="ref"}, [35](#jah34568-bib-0035){ref-type="ref"}, [36](#jah34568-bib-0036){ref-type="ref"}, [37](#jah34568-bib-0037){ref-type="ref"}, [38](#jah34568-bib-0038){ref-type="ref"}, [39](#jah34568-bib-0039){ref-type="ref"}, [40](#jah34568-bib-0040){ref-type="ref"}, [41](#jah34568-bib-0041){ref-type="ref"}, [42](#jah34568-bib-0042){ref-type="ref"}, [43](#jah34568-bib-0043){ref-type="ref"}, [44](#jah34568-bib-0044){ref-type="ref"}, [45](#jah34568-bib-0045){ref-type="ref"}, [46](#jah34568-bib-0046){ref-type="ref"}, [47](#jah34568-bib-0047){ref-type="ref"}, [48](#jah34568-bib-0048){ref-type="ref"}, [49](#jah34568-bib-0049){ref-type="ref"} or RR for mortality (*P*=0.871 at meta‐regression analysis) (Figure [S3](#jah34568-sup-0001){ref-type="supplementary-material"}).

###### 

Inferential Analysis Comparing Higher vs Lower Than Median Crossover Rate

  Variable                                                    Value, Count (%) or Median (First Quartile; Third Quartile)                       
  ----------------------------------------------------------- ------------------------------------------------------------- ------------------- ---------
  From experimental to control group                                                                                                            
  Year of publication                                         2010 (2004; 2014)                                             2010 (2008; 2012)   0.796
  Multicenter studies                                         20 (58.8)                                                     14 (42.2)           0.179
  Treatment features                                                                                                                            
  Coronary artery bypass graft trials                         31 (91.2)                                                     30 (90.9)           0.969
  Off‐pump coronary artery bypass graft trials                25 (73.5)                                                     14 (42.4)           0.010
  Valve trials                                                3 (8.8)                                                       9 (27.3)            0.049
  Experimental group more invasive than control group         7 (20.6)                                                      15 (45.5)           0.030
  End point features                                                                                                                            
  Mortality end point                                         26 (76.5)                                                     12 (36.4)           0.001
  Clinical end point                                          22 (64.7)                                                     11 (33.3)           0.010
  Patency end point                                           3 (8.8)                                                       13 (39.4)           0.003
  Statistical power, %                                        90 (80; 90)                                                   80 (80; 90)         0.290
  Expected relative risk reduction, %                         32 (28; 33)                                                   18 (15; 40)         0.227
  Sample size                                                 290 (176; 2394)                                               260 (150; 339)      0.123
  Follow‐up, mo                                               12 (1; 24)                                                    15 (1; 35)          0.228
  Crossover from control to experimental group, %             1.9 (0; 3.6)                                                  0.9 (0; 3.7)        0.722
  Total crossover, %                                          10.0 (8.7; 13.4)                                              3.0 (1.0; 5.4)      \<0.001
  Relative crossover                                          5.6 (2.3; 85.0)                                               1.0 (0.3; 10.0)     \<0.001
  Internal validity according to Cochrane Risk of Bias Tool                                                                                     
  High                                                        1 (2.9)                                                       7 (21.2)            0.003
  Moderate or uncertain                                       23 (67.7)                                                     25 (75.8)           
  Low                                                         10 (29.4)                                                     1 (3.0)             
  Main findings for primary end point                                                                                                           
  Favors experimental group                                   2 (5.9)                                                       11 (33.3)           0.016
  Favors control group                                        2 (5.9)                                                       2 (6.1)             
  Nonsignificant                                              30 (88.2)                                                     20 (60.6)           
  Relative risk for primary end point                         1.00 (0.91; 1.22)                                             0.77 (0.52; 1.00)   0.054
  Relative risk for mortality                                 1.02 (0.93; 1.30)                                             0.88 (0.61; 1.03)   0.022
  From control to experimental group                                                                                                            
  Year of publication                                         2011 (2009; 2014)                                             2008 (2004; 2011)   0.055
  Multicenter studies                                         24 (70.6)                                                     10 (30.3)           0.001
  Treatment features                                                                                                                             
  Coronary artery bypass graft trials                         33 (97.1)                                                     28 (84.9)           0.080
  Off‐pump coronary artery bypass graft trials                19 (55.9)                                                     20 (60.6)           0.695
  Valve trials                                                4 (11.8)                                                      8 (24.2)            0.183
  Experimental group more invasive than control group         13 (38.2)                                                     9 (27.3)            0.339
  End point features                                                                                                                            
  Mortality end point                                         23 (67.7)                                                     15 (45.5)           0.067
  Clinical end point                                          21 (61.8)                                                     12 (36.4)           0.038
  Patency end point                                           7 (20.6)                                                      9 (27.3)            0.521
  Statistical power, %                                        82 (80; 90)                                                   80 (80; 90)         0.721
  Expected relative risk reduction, %                         28 (20; 33)                                                   30 (14; 50)         0.926
  Sample size                                                 475 (301; 2394)                                               176 (120; 251)      \<0.001
  Follow‐up, mo                                               12 (1; 60)                                                    12 (1; 24)          0.275
  Internal validity according to Cochrane Risk of Bias Tool                                                                                     
  High                                                        4 (11.8)                                                      4 (12.1)            0.642
  Moderate or uncertain                                       23 (67.7)                                                     25 (75.8)           
  Low                                                         7 (20.6)                                                      4 (12.1)            
  Crossover from experimental to control group, %             7.0 (3.9; 12.4)                                               7.4 (1.0; 9.0)      0.269
  Total crossover, %                                          10.0 (8.7; 13.4)                                              3.0 (1.0; 5.4)      0.074
  Relative crossover                                          1.9 (1.0; 3.4)                                                16.6 (5.3; 85.0)    \<0.001
  Main findings for primary end point                                                                                                           
  Favors experimental group                                   3 (8.8)                                                       1 (3.0)             0.065
  Favors control group                                        3 (8.8)                                                       10 (30.3)           
  Nonsignificant                                              28 (82.4)                                                     22 (66.7)           
  Relative risk for primary end point                         0.98 (0.83; 1.14)                                             0.78 (0.52; 1.08)   0.468
  Relative risk for mortality                                 1.01 (0.91; 1.28)                                             0.92 (0.70; 1.29)   0.174

Higher or equal to the median.

Lower than the median.

###### 

Meta‐Regression Analysis Exploring Potential Moderators of Effect Sizes

  Variable                                                  Coefficient (95% CI)        *P* Value   τ^2^    Adjusted *R* ^2^
  --------------------------------------------------------- --------------------------- ----------- ------- ------------------
  Logarithm of the relative risk of the primary end point                                                   
  Year of publication                                       −0.002 (−0.031 to 0.027)    0.904       0.055   0.118
  Multicenter studies                                       −0.091 (−0.366 to 0.183)    0.504       0.054   0.559
  Coronary artery bypass graft trials                       0.256 (0.015 to 0.497)      0.038       0.040   0.194
  Off‐pump coronary artery bypass graft trials              0.256 (0.015 to 0.497)      0.038       0.040   0.513
  Valve trials                                              −0.290 (−0.637 to 0.057)    0.099       0.045   0.075
  Experimental group more invasive than control group       −0.245 (−0.489 to −0.001)   0.049       0.038   0.239
  Mortality end point                                       0.216 (−0.040 to 0.472)     0.096       0.020   0.595
  Clinical end point                                        0.153 (−0.102 to 0.409)     0.232       0.035   0.284
  Patency end point                                         −0.066 (−0.376 to 0.244)    0.670       0.049   0.003
  Statistical power, %                                      −0.070 (−2.786 to 2.646)    0.958       0.058   0.633
  Expected relative risk reduction, %                       −0.014 (−0.028 to 0.001)    0.067       0       0.104
  Sample size                                               0.000 (0.000 to 0.000)      0.292       0.047   0.542
  Follow‐up, mo                                             0.002 (−0.002 to 0.006)     0.336       0.041   0.532
  High internal validity                                    −0.083 (0.426 to 0.260)     0.625       0.048   0.534
  High, moderate, or uncertain validity                     −0.076 (−0.408 to 0.256)    0.644       0.054   0.556
  Crossover from experimental to control group, %           0.027 (0.001 to 0.053)      0.040       0.025   0.474
  Crossover from control to experimental group, %           −0.010 (−0.068 to 0.048)    0.726       0.056   0.556
  Total crossover, %                                        0.027 (0.002 to 0.052)      0.037       0.025   0.469
  Relative crossover                                        −0.001 (−0.007 to 0.004)    0.640       0.052   0.556
  Logarithm of the relative risk of mortality                                                               
  Year of publication                                       −0.003 (−0.037 to 0.031)    0.842       0.099   0.488
  Multicenter studies                                       −0.059 (−0.374 to 0.257)    0.710       0.099   0.490
  Coronary artery bypass graft trials                       0.346 (−0.268 to 0.959)     0.262       0.093   0.013
  Off‐pump coronary artery bypass graft trials              0.313 (0.041 to 0.585)      0.025       0.062   0.324
  Valve trials                                              −0.284 (−0.703 to 0.134)    0.178       0.092   0.001
  Experimental group more invasive than control group       −0.223 (−0.537 to 0.090)    0.157       0.083   0.099
  Mortality end point                                       0.218 (−0.125 to 0.560)     0.207       0.087   0.055
  Clinical end point                                        0.212 (−0.108 to 0.532)     0.188       0.089   0.034
  Patency end point                                         −0.306 (−0.700 to 0.088)    0.125       0.090   0.026
  Statistical power, %                                      −1.945 (−4.607 to 0.716)    0.147       0.076   0.472
  Expected relative risk reduction, %                       −0.003 (−0.040 to 0.033)    0.824       0.027   0.573
  Sample size                                               0.000 (0.000 to 0.000)      0.519       0.010   0.476
  Follow‐up, mo                                             0.002 (−0.003 to 0.007)     0.446       0.099   0.488
  High internal validity                                    −0.405 (−0.834 to 0.025)    0.064       0.079   0.439
  High, moderate, or uncertain validity                     0.060 (−0.341 to 0.461)     0.764       0.102   0.488
  Crossover from experimental to control group, %           0.040 (0.008 to 0.071)      0.015       0.073   0.399
  Crossover from control to experimental group, %           0.005 (−0.062 to 0.073)     0.871       0.100   0.086
  Total crossover, %                                        0.037 (0.006 to 0.067)      0.021       0.076   0.405
  Relative crossover                                        −0.001 (−0.006 to 0.005)    0.815       0.097   0.486

![Forest plot for the relative risk of the primary end point, with studies subgrouped and then sorted according to decreasing rate of crossover from experimental group (EG) to control group (CG). All relative risks were calculated as \>1 favored the CG and \<1 favored the EG. Between‐group heterogeneity *P*=0.017. ART, Randomized Trial of Bilateral versus Single Internal‐Thoracic‐Artery Grafts; BBS, Best Bypass Surgery Trial; BHACAS, Beating Heart Against Cardioplegic Arrest Studies; CARRPO, Copenhagen Arterial Revascularization Randomized Patency and Outcome Trial; CORONARY, CABG Off or On Pump Revascularization Study; CRISP, Coronary artery bypass grafting in high‐risk patients randomised to off‐ or on‐pump surgery; CTSNET AFIB, Cardiothoracic Surgical Trials Network ‐ Surgical Ablation of Atrial Fibrillation during Mitral‐Valve Surgery; DOORS, Danish On‐Pump Versus Off‐Pump Randomization Study; GOPCABE, German Off Pump Coronary Artery Bypass in Elderly Study; MASS, Medicine, Angioplasty, or Surgery Study; OCTOPUS, A Comparison of On‐Pump and Off‐Pump Coronary Bypass Surgery in Low‐Risk Patients; PRAGUE 6, Off‐Pump Versus On Pump Coronary Artery Bypass Graft Surgery in Patients With EuroSCORE ≥6; PROMISS, Prospective Randomized Comparison of Off‐Pump and On‐Pump Multi‐vessel Coronary Artery Bypass Surgery; RAPCO SVG, Radial Artery Patency; and Clinical Outcomes trial ‐ saphenous vein graft arm; RAPCO RITA, Radial Artery Patency; and Clinical Outcomes trial ‐ right internal thoracic artery arm; RAPS, radial artery patency study; REGROUP, Randomized Endo‐Vein Graft Prospective; RESTORE‐MV, Randomized Evaluation of a Surgical Treatment for Off‐Pump Repair of the Mitral Valve; ROOBY, Randomized On/Off Bypass; RSVP, Radial Artery Versus Saphenous Vein Patency Trial; STICH, Surgical Treatment for Ischemic Heart Failure.](JAH3-8-e013711-g001){#jah34568-fig-0001}
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Another additional important finding of meta‐regression analysis was the significant association between the RR for the primary end point (*P*=0.038) and for mortality (*P*=0.025) with off‐pump CABG, with effect estimates significantly in favor of the control intervention (ie, on‐pump CABG). Other nominally significant associations with the RR for the primary end point or for mortality occurred for the following: rate of crossover from experimental to control group (Figures [S4](#jah34568-sup-0001){ref-type="supplementary-material"} and [S5](#jah34568-sup-0001){ref-type="supplementary-material"}); CABG trials; and trials allocating more invasive treatments to the experimental arm. Accompanying L\'Abbè plots for the association between the rate of crossover from control to experimental group and the RRs for the primary end point and mortality are provided in Figures [S6](#jah34568-sup-0001){ref-type="supplementary-material"} and [S7](#jah34568-sup-0001){ref-type="supplementary-material"}. Visual inspection highlights the lack of an evident crossover threshold.

Exploratory analysis to identify multivariable predictors of crossover (Table [S4](#jah34568-sup-0001){ref-type="supplementary-material"}) suggested that crossover from experimental to control group was mostly associated with patency as primary end point (*P*=0.036). In addition, meta‐regression focusing on *total crossover* rate instead of relative crossover confirmed the overall findings (Table [3](#jah34568-tbl-0003){ref-type="table"}), with significant associations found for this composite variable and the RR for the primary end point (*P*=0.037) and for mortality (*P*=0.021). In contrast, *relative crossover* was not significantly associated with significant effect on the RR. Last, sensitivity analysis using \|LogRR\| (Table [S5](#jah34568-sup-0001){ref-type="supplementary-material"}) showed that CABG trials (*P*=0.012), trials with a mortality end point (*P*\<0.001), trials with a clinical end point (*P*=0.044), sample size (*P*=0.006), follow‐up (*P*=0.023), study validity (*P*=0.022), crossover from experimental to control group (*P*=0.007), and total crossover (*P*=0.005) were significantly associated with the \|LogRR\| for the primary end point. Furthermore, year of publication (*P*=0.034), multicenter design (*P*\<0.001), sample size (*P*=0.004), study validity (*P*=0.009), and crossover from control to experimental group (*P*=0.021) were significantly associated with the \|LogRR\| for mortality. Finally, visual inspection of funnel plots showed borderline small study effects/publication bias for the RR of the primary end point and no significant small study effects/publication bias for the RR of mortality (Figures [S8](#jah34568-sup-0001){ref-type="supplementary-material"} and [S9](#jah34568-sup-0001){ref-type="supplementary-material"}).

Discussion {#jah34568-sec-0018}
==========

The optimal approach to personalized medicine and therapeutics entails a complex synthesis of diagnostic and treatment skills. Cardiac surgical management, arguably, appears particularly demanding as surgeons have to master advanced technical requirements while applying evidence‐based recommendations. As such, clinical research designed and conducted in this particularly challenging scenario, with uncertain applicability and generalizability, requires careful scrutiny of its strengths and weaknesses. By including all RCTs focusing on cardiac surgical interventions, we hereby provide a comprehensive and updated perspective on the prevalence of crossover from experimental to control group and vice versa in cardiac surgery RCTs, highlighting the detrimental impact of high crossover from experimental to control group in terms of effect dilution for the primary end point and for mortality. We corroborate these findings using a comprehensive estimate of crossover and absolute effect estimates, thus in a more generalistic context.

By definition, crossover dilutes the treatment effect in the intention‐to‐treat analysis. It has been estimated that, for a fixed sample size and power, the increase of the crossover rate from 0% to 25% may reduce the power of the study from 77% to 57%.[6](#jah34568-bib-0006){ref-type="ref"} In surgical RCTs, things are even more complex, as crossover rate from the experimental to the control group may be to be a marker of a lack of familiarity of the participating surgeons with the (usually new or more complex) surgical procedure performed in the experimental arm. In this case, the association between crossover and outcome may overcome the purely statistical diluting effect of crossover in general and suggests a problem with the deliverability of the procedure. In fact, crossover has been associated with learning curve, as well as with suboptimal technical and clinical results in surgical RCTs.[5](#jah34568-bib-0005){ref-type="ref"}, [10](#jah34568-bib-0010){ref-type="ref"}

Crossover rate from off‐pump to on‐pump CABG was used as a surrogate for surgeon\'s experience by Gaudino et al.[10](#jah34568-bib-0010){ref-type="ref"} By pooling data from 104 RCTs (20 627 patients), the authors showed a statistically significant excess risk of late mortality in the off‐pump CABG group for studies with a crossover rate ≥10% (incidence rate ratio, 1.30; 95% CI, 1.04--1.62); moreover, at meta‐regression, there was a correlation between the proportion of patients who crossed over from off‐pump to on‐pump CABG and the rate of incomplete revascularization in the off‐pump CABG arm (β=0.0019; *P*=0.03).

In a systematic review of all RCTs comparing minimally invasive surgery with open surgery for gastrointestinal cancer, surgical experience showed an inverse relationship with crossover (β=−2.344; *P*=0.037). At multivariate analysis, a statistically significant correlation between crossover to the open surgery arm and 30‐day mortality (β=0.125; *P*=0.033), anastomotic leak rate (β=0.550; *P*=0.004), and early complications (β=1.255; *P*=0.001) was found.[5](#jah34568-bib-0005){ref-type="ref"}

Our analysis cannot shed a conclusive light on the existence of a level of crossover where the results of the intention‐to‐treat analysis are by definition invalidated. Similarly, we could not find a safety threshold for crossover, below which results of an RCT can be considered bulletproof. Clearly, the complex relation between the crossover, event rate, power, and sample size must be considered on a case‐by‐case basis. For studies with few events and high crossover rates, major concerns may exist. Pragmatically, we propose that optimal crossover rates should arguably be \<5%. The use of entry criteria for surgeons' experience, pretrial training, and close monitoring of crossover rate should be implemented in every surgical RCT to ensure the methodological validity of the trial.

Yet, an RCT does not necessarily correspond to clinical practice, and the design of RCTs is typically based on phase 3 pharmacologic trials. Focusing on the percutaneous coronary intervention versus CABG comparison, for instance, randomization typically occurs after coronary angiography. In addition, it is often the case that percutaneous coronary intervention and CABG are considered complementary, rather than alternative and competing treatments, as in many hybrid revascularization studies. Furthermore, percutaneous coronary intervention after CABG and CABG after percutaneous coronary intervention may also represent disease progression, rather than failure of the initial treatment strategy. Finally, it should be borne in mind that "pure treatment" should not be equated to "intention to treat," and that our work mainly focuses on the features of surgical RCTs according to crossover from pure treatment. Indeed, in selected instances, crossover from pure treatment may actually be correctly mirroring best clinical practice and, thus, be appropriate and justifiable.

Our analysis was also limited to cardiac surgery RCTs where one may argue that the level of technical complexity is usually higher than in other fields of surgery. It is possible that the strength of the association between crossover rate and outcome is different in other surgical or medical specialties. However, our focus on a discipline, such as cardiac surgery, that entails complex organizational and procedural hurdles and involves patients at high risk provides a powerful data set capable of informing on the impact of crossover in surgical trials. Another important limitation of our work is that the included RCTs tested different interventions with different levels of technical complexity and it is likely that the association between crossover and outcome may be different for different procedures. Indeed, statistical heterogeneity was significant in our analysis, as can be expected when appraising studies focusing on heterogeneous end points and interventions. Also, some trial was powered for and reported multiple comparisons, and our model did not adjust for possible interactions. In addition, our work shares all the common limitations of meta‐epidemiologic studies, including ecological fallacy, selective reporting, small study effect, and residual confounding. Accordingly, our analysis remains a constructive critique to modern cardiac surgery RCTs, hopefully suitable to inform the conduct, analysis, and interpretation of ongoing and future trials in this field and arguably in other medical and surgical disciplines as well.

In conclusion, we have shown that crossover, particularly from experimental to control group, is associated with outcome, including mortality, in cardiac surgery RCTs. Crossover should be minimized when designing RCTs, and carefully appraised after their completion, to maximize the chance of methodological success and efficient resource use.
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